Intellia Therapeutics price target raised to $91 from $89 at BofA

BofA analyst Greg Harrison raised the firm’s price target on Intellia Therapeutics to $91 from $89 and keeps a Buy rating on the shares following what the firm calls “an impressive update” from its phase 1 trial of NTLA-2002 in hereditary angioedema, or HAE. In addition to incrementally derisking another commercial opportunity, the update provides “further validation to Intellia’s gene editing platform,” contends the firm.